Pacific Biosciences of California, Inc. (PACB)

NASDAQ: PACB · IEX Real-Time Price · USD
1.870
-0.070 (-3.61%)
At close: May 24, 2024, 4:00 PM
1.890
+0.020 (1.07%)
After-hours: May 24, 2024, 7:59 PM EDT
-3.61%
Market Cap 509.31M
Revenue (ttm) 200.43M
Net Income (ttm) -296.90M
Shares Out 272.36M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,969,210
Open 1.980
Previous Close 1.940
Day's Range 1.855 - 2.030
52-Week Range 1.250 - 14.550
Beta 1.98
Analysts Buy
Price Target 6.59 (+252.41%)
Earnings Date May 9, 2024

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified D... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Oct 27, 2010
Employees 796
Stock Exchange NASDAQ
Ticker Symbol PACB
Full Company Profile

Financial Performance

In 2023, PACB's revenue was $200.52 million, an increase of 56.29% compared to the previous year's $128.30 million. Losses were -$306.74 million, -2.39% less than in 2022.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is $6.59, which is an increase of 252.41% from the latest price.

Price Target
$6.59
(252.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases

Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif.

11 days ago - PRNewsWire

PacBio Announces First Quarter 2024 Financial Results

MENLO PARK, Calif. , May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024.

17 days ago - PRNewsWire

PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance

Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. , April 16, 2024  /PRNewswire/ – PacBi...

5 weeks ago - PRNewsWire

Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

HiFi Data Generated on the Revio™  System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, ...

2 months ago - PRNewsWire

PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of t...

2 months ago - PRNewsWire

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: GUTSIVPMTEMOM
2 months ago - Benzinga

PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions

HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif. , March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading de...

2 months ago - PRNewsWire

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March - Ironwood Pharmaceuticals (NASDAQ:IRWD), Integra Lifesciences (NASDAQ:IART)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: IARTIRWD
2 months ago - Benzinga

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif. , Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participati...

3 months ago - PRNewsWire

PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results

MENLO PARK, Calif. , Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023.

3 months ago - PRNewsWire

Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch

ATLANTA , Feb. 13, 2024 /PRNewswire/ -- VOLO Events Agency (VOLO), a leading producer of experiential marketing and live events for global brands, has won the best Event Technology award at the BizBas...

3 months ago - PRNewsWire

PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale

New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™  Sequencing System MENLO PARK, Calif. , Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of hi...

3 months ago - PRNewsWire

PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024

MENLO PARK, Calif. , Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursda...

4 months ago - PRNewsWire

PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions

Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and Bacteria MENLO PARK, Calif. , Jan. 15, 2024 /PRNewswire/ -- PacBio (NA...

4 months ago - PRNewsWire

PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively

Ships a record number of PacBio sequencers in 2023, including 173 Revio™ systems, and announces record fourth quarter preliminary consumable revenue of $18.9 million as demand for long-read sequencing...

4 months ago - PRNewsWire

PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif. , Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting ...

5 months ago - PRNewsWire

PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors

MENLO PARK, Calif. , Dec. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that David Botstein, Ph.D.

5 months ago - PRNewsWire

PacBio Announces HiFi Solves, a Global Consortium of Clinical Genomics Research Leaders

Consortium Aims to Share Best Practices and Increase our Understanding of Genetic Disease MENLO PARK, Calif. , Nov. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, ...

7 months ago - PRNewsWire

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partners to PacBio Compatible

Partnerships Maximize Value of HiFi Data and Complete the Full End-to-End Workflow for PacBio Customers. MENLO PARK, Calif.

7 months ago - PRNewsWire

PacBio Announces Kinnex RNA Kits, Further Scaling HiFi Sequencing in Full-Length RNA, Single-Cell RNA and 16S rRNA Applications

Building on the MAS-Seq Concatenation Method, These Three New Kits can Significantly Increase Throughput in RNA Applications MENLO PARK, Calif. , Oct. 31, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a...

7 months ago - PRNewsWire

PacBio Announces Third Quarter 2023 Financial Results

MENLO PARK, Calif. , Oct. 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023.

7 months ago - PRNewsWire

PacBio Announces Appointment of David Meline to Board of Directors

Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board MENLO PARK, Calif. , Oct. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-qua...

7 months ago - PRNewsWire

PacBio to Report Third Quarter 2023 Financial Results on October 30, 2023

MENLO PARK, Calif. , Oct. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2023 financial results on Monday, ...

8 months ago - PRNewsWire

PacBio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

PacBio WGS Variant Pipeline Will Bring Standardization to PacBio HiFi Data Analysis MENLO PARK, Calif. , Oct. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highl...

8 months ago - PRNewsWire

PacBio Announces PacBio Capital

New Program Expands Access to PacBio's Highly Accurate Sequencing Systems by Providing Flexible Financing   MENLO PARK, Calif. , Sept. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading develop...

9 months ago - PRNewsWire